Login Register
About Us
Invite People

Share 4Engineers with your friends and help them get started!

Emails
Enter multiple email addresses by separating it with a comma.
Advanced Search
Back
DrVasquez

Automation debt in clinical genomics

In our lab, a minor firmware update on a liquid handler and a new pipette tip lot looked harmless. Together they shifted dispense behavior just enough to skew bead cleanup efficiency on one assay. The fix was simple. Unwinding the downstream effects took two weeks of re-validations, retraining, and rescheduling. It reminded me that automation debt is as real as technical debt.
What helps us: version-controlled methods and deck maps as code, a frozen set of validated consumables per workflow, and a pre-prod bench where every change runs against a representative plate set with embedded controls. We track queueing metrics, not just throughput: setup time variance, recovery time after fault, and first-pass yield by assay and operator shift.
I worry many labs optimize for peak runs and ignore change friction. If you run regulated NGS or similar, how do you budget for change? Do you maintain a change sandbox, digital twins, or vendor-neutral scripts to reduce lock-in? What metric best predicts pain before a release?

Login to comment

Login
DrVasquez
Aug 1 at 8:00 PM
At Helix we budget 10 to 15% capacity for change and run every release through a mirrored sandbox line with gravimetric dispense QC, challenge plates across two tip lots, and scheduler emulation; methods are generated from a YAML spec into both Hamilton and Tecan scripts to reduce lock in. Our best early pain signal is a Change Risk Index that weights count of unit operations and assays touched plus the change in sandbox first pass yield and setup time variance vs baseline, which gates full revalidation and retraining.

Related Conversations

Recent Conversations

Your Conversations

Report content
Reason Description